Low-Dose Oral Tranexamic Acid as a Standard Treatment for Melasma: Are We There Yet?

Abstract

Keywords

melasma tranexamic acid thromboembolism

Get full access to this article

View all access options for this article.

References

Godse

Sarkar

Mysore

, et al Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts. Indian J Dermatol. 2023;68(2):178-185. doi:10.4103/ijd.ijd_266_22

Kuceki

Mendez

Garza-Dueñas

Kruithoff

Fonseca

Lal

No thromboembolic events observed in RCTs of oral tranexamic acid: a systematic review and descriptive synthesis. J Am Acad Dermatol. 2025;93(4):1086-1088. doi:10.1016/j.jaad.2025.06.001

Lee

Thng

Goh

CL.

Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392. doi:10.1016/j.jaad.2016.03.001

Meaidi

Mørch

Torp-Pedersen

Lidegaard

Oral tranexamic acid and thrombosis risk in women. EClinicalMedicine. 2021;35:100882. doi:10.1016/j.eclinm.2021.100882

Lam

Mansour

Sutton

Oral tranexamic acid treatment beyond 6 months for melasma patients—a retrospective case series. JAAD Int. 2024;15:195-196. doi:10.1016/j.jdin.2024.03.006